Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, CXP, MAT

Khiron Expands to Europe, Signs Non-Binding LOI to Acquire Italy-Based Canapalife Group



TORONTO, April 25, 2019 /PRNewswire/ -- Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a medical cannabis company with its core operations in Latin America, announced today that the Company has entered into a non-binding letter of agreement to acquire 100% of the outstanding securities of Canapalife S.r.l. and 100% of the economic interest in Campodoro S.r.l. ("Canapalife Group") from Alvaro Garro and Paolo Puggioni (the "Vendors"), being the sole shareholders of Canapalife Group.

Canapalife is a prominent hemp product company based in Italy with licenses for the cultivation, research, production and marketing of hemp-based products. Canapalife operates a cultivation site in Padua, near Venice, Italy, conducts research in partnership with prominent universities and has registered three CBD consumer brands, including, Bloom CBD e-liquids, Canvax nutraceutical products and Legal Seeds, a brand designed to market EU approved seeds to the consumer market. These products are in-market through established partnerships with pharmacies and independent retail chains across Italy.

Italy represents the fourth largest economy in Europe, and is the second largest cannabis market in Europe, with a projected medical cannabis market value of ? 7.5 Billion in 2028 (Source: Prohibition Partners ? The European Cannabis Report, January 2019).

Alvaro Torres, Khiron CEO and Director commented, "The proposed transaction offers Khiron an entry to the European market and expansion of our global footprint. In addition to increasing our multi-jurisdiction cultivation and production capacity, Canapalife offers the addition of dynamic brands to our product portfolio, access to key retailer partners and relationships with Italy's leading research facilities."

Upon completion of the acquisition of Canapalife Group, it is anticipated that each of Mr. Garro and Mr. Puggioni, the sole shareholders of Canapalife Group, will continue on as key employees with Khiron. Closing of the transaction is anticipated to be the end of Q2.

As consideration for the acquisition of Canapalife Group, Khiron will issue such number of common shares as is equal to C$10,500,000 (the "Purchase Price") at a deemed price per share equal to the trailing 20 day volume weighted average closing price of its common shares on the TSX Venture Exchange ("TSXV"). An earn out of additional common shares for up to C$4,500,000, will be payable by Khiron to the Vendors over the course of two years subject to Canapalife Group attaining certain revenue milestones.

Hillcrest Merchant Partners Inc. acted as advisor on this agreement. Completion of the transaction, and issuance of any finder's fee, is subject to the execution of a definitive agreement and receipt of all required regulatory approvals, including final acceptance of the TSXV.

About CanapaLife Group

Canapalife is a producer and processor of hemp products in Italy and the leader in the research and development of new hemp food ingredients. The company collaborates with universities, research institutes and organizations from the food, materials, pharmaceutical and cosmetics industries. The company's main products are hemp flowers and CBD oil extract, with development underway for new products based on CBD resin and food product based on hemp seeds. Canapalife actively promotes the development of a sustainable industrial hemp processing industry in Europe by working closely with strategic partners, government agencies, and producer associations. Canapalife's mission is to be the leading manufacturer and preferred supplier of certified hemp products and ingredients to a network of global customers. Further information can be found at https://www.canapalife.it

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian-based medical cannabis companies to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/

To be added to the distribution list, please email [email protected] with "Khiron" in the subject line.

Cautionary Notes

Forward-Looking Statements
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by  statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the execution of a definitive agreement, receipt of required regulatory approvals, including the TSXV. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: [email protected]; Phil Carlson, KCSA Strategic Communications, 212-896-1233, E: [email protected]; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: [email protected]

 



These press releases may also interest you

at 21:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today published a report titled 'Unlocking the Infinite Potential of Crypto and AI.' The report explores the convergence of AI and crypto, a major trend in...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:45
The "Austria Social Commerce Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs on Social Commerce Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics - Q1 2024 Update" report has been added...

at 20:40
Osisko Development Corp. ("Osisko Development" or the "Company") reports its financial and operating results for the three and twelve months ended December 31, 2023 ("Q4 2023"). Q4 2023 HIGHLIGHTS Operating, Financial and Corporate Updates: 2,090...

at 20:39
TSX VENTURE COMPANIES BULLETIN V2024-0926 VALLEYVIEW RESOURCES LTD. ("VVR")BULLETIN TYPE:  Resume TradingBULLETIN DATE: March 28, 2024TSX Venture Tier 2 Company Reference is made to our bulletin dated March 26, 2024 with respect to the listing of the...

at 20:30
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sonder Holdings Inc. resulting from allegations that Sonder may have issued materially misleading business...



News published on and distributed by: